Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Structural and functional consequences of the STAT5BN642H driver mutation.

de Araujo ED, Erdogan F, Neubauer HA, Meneksedag-Erol D, Manaswiyoungkul P, Eram MS, Seo HS, Qadree AK, Israelian J, Orlova A, Suske T, Pham HTT, Boersma A, Tangermann S, Kenner L, Rülicke T, Dong A, Ravichandran M, Brown PJ, Audette GF, Rauscher S, Dhe-Paganon S, Moriggl R, Gunning PT.

Nat Commun. 2019 Jun 7;10(1):2517. doi: 10.1038/s41467-019-10422-7.

PMID:
31175292
2.

Cell Metabolism Control Through O-GlcNAcylation of STAT5: A Full or Empty Fuel Tank Makes a Big Difference for Cancer Cell Growth and Survival.

Rauth M, Freund P, Orlova A, Grünert S, Tasic N, Han X, Ruan HB, Neubauer HA, Moriggl R.

Int J Mol Sci. 2019 Feb 27;20(5). pii: E1028. doi: 10.3390/ijms20051028. Review.

3.

Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma.

Neubauer HA, Tea MN, Zebol JR, Gliddon BL, Stefanidis C, Moretti PAB, Pitman MR, Costabile M, Kular J, Stringer BW, Day BW, Samuel MS, Bonder CS, Powell JA, Pitson SM.

Oncogene. 2019 Feb;38(8):1151-1165. doi: 10.1038/s41388-018-0504-9. Epub 2018 Sep 24.

4.

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.

Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Müller M, Moriggl R.

Leukemia. 2018 Aug;32(8):1713-1726. doi: 10.1038/s41375-018-0117-x. Epub 2018 Mar 27. Review.

5.

NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.

Seidi K, Jahanban-Esfahlan R, Monhemi H, Zare P, Minofar B, Daei Farshchi Adli A, Farajzadeh D, Behzadi R, Mesgari Abbasi M, Neubauer HA, Moriggl R, Zarghami N, Javaheri T.

Oncogene. 2018 Jul;37(29):3967-3980. doi: 10.1038/s41388-018-0213-4. Epub 2018 Apr 17.

6.

Tumor target amplification: Implications for nano drug delivery systems.

Seidi K, Neubauer HA, Moriggl R, Jahanban-Esfahlan R, Javaheri T.

J Control Release. 2018 Apr 10;275:142-161. doi: 10.1016/j.jconrel.2018.02.020. Epub 2018 Feb 16. Review.

PMID:
29454742
7.

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.

Orlova A, Wingelhofer B, Neubauer HA, Maurer B, Berger-Becvar A, Keserű GM, Gunning PT, Valent P, Moriggl R.

Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi: 10.1080/14728222.2018.1406924. Epub 2017 Nov 24. Review.

8.

CIB2 Negatively Regulates Oncogenic Signaling in Ovarian Cancer via Sphingosine Kinase 1.

Zhu W, Jarman KE, Lokman NA, Neubauer HA, Davies LT, Gliddon BL, Taing H, Moretti PAB, Oehler MK, Pitman MR, Pitson SM.

Cancer Res. 2017 Sep 15;77(18):4823-4834. doi: 10.1158/0008-5472.CAN-17-0025. Epub 2017 Jul 20.

9.

Validation of commercially available sphingosine kinase 2 antibodies for use in immunoblotting, immunoprecipitation and immunofluorescence.

Neubauer HA, Pitson SM.

Version 2. F1000Res. 2016 Dec 6 [revised 2017 Jan 1];5:2825. doi: 10.12688/f1000research.10336.2. eCollection 2016.

10.

An oncogenic role for sphingosine kinase 2.

Neubauer HA, Pham DH, Zebol JR, Moretti PA, Peterson AL, Leclercq TM, Chan H, Powell JA, Pitman MR, Samuel MS, Bonder CS, Creek DJ, Gliddon BL, Pitson SM.

Oncotarget. 2016 Oct 4;7(40):64886-64899. doi: 10.18632/oncotarget.11714.

11.

Roles, regulation and inhibitors of sphingosine kinase 2.

Neubauer HA, Pitson SM.

FEBS J. 2013 Nov;280(21):5317-36. doi: 10.1111/febs.12314. Epub 2013 Jun 7. Review.

12.

Dissection of an allosteric mechanism on the serotonin transporter: a cross-species study.

Neubauer HA, Hansen CG, Wiborg O.

Mol Pharmacol. 2006 Apr;69(4):1242-50. Epub 2006 Jan 24.

PMID:
16434615
13.

Characterization of an allosteric citalopram-binding site at the serotonin transporter.

Chen F, Larsen MB, Neubauer HA, Sánchez C, Plenge P, Wiborg O.

J Neurochem. 2005 Jan;92(1):21-8.

Supplemental Content

Loading ...
Support Center